1. [CASE 1 — QUESTION 1]
A 66-year-old man underwent coronary stenting three weeks ago and is on dual antiplatelet therapy with aspirin and clopidogrel, a prodrug that requires CYP2C19 (cytochrome P450 2C19) activation to inhibit platelets. He now has frequent daytime reflux, and his cardiologist asks you to start acid suppression while preserving the effectiveness of his antiplatelet therapy. He is not at high gastrointestinal bleeding risk. Which proton pump inhibitor is the most appropriate initial choice?
A) Omeprazole, the most established agent
B) Pantoprazole, because it has minimal CYP2C19 inhibitory activity and is least likely to reduce clopidogrel activation
C) Esomeprazole, the S-enantiomer of omeprazole
D) High-dose omeprazole to override the interaction
E) Cimetidine, an H2 receptor antagonist
ANSWER: B
Rationale:
Clopidogrel must be activated by CYP2C19, so a proton pump inhibitor that inhibits CYP2C19 can blunt its antiplatelet effect. Pantoprazole exerts minimal CYP2C19 inhibition and is the preferred agent when a proton pump inhibitor is needed alongside clopidogrel in a patient not at high gastrointestinal bleeding risk.
Option A: Option A is incorrect: omeprazole is a significant CYP2C19 inhibitor and is exactly what to avoid here.
Option C: Option C is incorrect: esomeprazole also inhibits CYP2C19 and shares the interaction.
Option D: Option D is incorrect: raising the omeprazole dose increases, not overrides, CYP2C19 inhibition.
Option E: Option E is incorrect: cimetidine is a broad CYP inhibitor and is not an enzyme-neutral choice.
2. [CASE 1 — QUESTION 2]
Continuing with the same patient. You have selected pantoprazole. He asks when he should take it, mentioning that he usually takes all his pills together at bedtime for convenience. What instruction will maximize acid suppression, and why?
A) Take it at bedtime with his other medications, since timing does not matter
B) Take it with the largest meal of the day
C) Take it immediately after breakfast once symptoms appear
D) Take it about 30 to 60 minutes before breakfast, because a proton pump inhibitor can only inactivate actively secreting pumps, and pre-meal dosing aligns peak drug levels with the meal-stimulated surge in pump activity
E) Take it only on days he has symptoms
ANSWER: D
Rationale:
A proton pump inhibitor inactivates only pumps that are actively secreting and therefore exposed to canalicular acid. Taking it 30 to 60 minutes before the first meal times peak plasma levels to the meal-driven surge in parietal cell activity, maximizing the fraction of pumps inhibited; bedtime dosing on an empty stomach reaches few active pumps.
Option A: Option A is incorrect: timing relative to meals is precisely what determines efficacy.
Option B: Option B is incorrect: the instruction is to dose before the first meal, not specifically the largest meal.
Option C: Option C is incorrect: dosing after the meal misses the window, since peak levels then arrive after the secretory surge has begun.
Option E: Option E is incorrect: intermittent symptom-driven dosing does not provide the sustained suppression he needs and undermines steady-state inhibition.
3. [CASE 1 — QUESTION 3]
Continuing with the same patient. Testing reveals Helicobacter pylori infection, and genotyping shows he is a CYP2C19 (cytochrome P450 2C19) ultrarapid metabolizer. Knowing that eradication depends on adequate acid suppression to support antibiotic activity, how should this influence the proton pump inhibitor component of his eradication regimen?
A) Use a higher proton pump inhibitor dose or select rabeprazole, because an ultrarapid metabolizer clears proton pump inhibitors quickly, achieving less acid suppression, which lowers intragastric pH and reduces antibiotic efficacy and eradication rates
B) Lower the proton pump inhibitor dose, since ultrarapid metabolizers over-suppress acid
C) Omit the proton pump inhibitor entirely so the antibiotics are not inhibited
D) Metabolizer status is irrelevant to eradication, so make no change
E) Replace the antibiotics with an H2 receptor antagonist
ANSWER: A
Rationale:
An ultrarapid metabolizer clears proton pump inhibitors rapidly, achieving lower and less sustained acid suppression. Because antibiotic activity against Helicobacter pylori is favored by a sufficiently high intragastric pH, weaker suppression reduces eradication success. The remedy is to deepen and sustain suppression — a higher proton pump inhibitor dose or rabeprazole, whose exposure is least sensitive to CYP2C19.
Option B: Option B is incorrect: ultrarapid metabolizers under-suppress, not over-suppress.
Option C: Option C is incorrect: removing the proton pump inhibitor lowers pH and reduces antibiotic efficacy.
Option D: Option D is incorrect: metabolizer status affects eradication through acid suppression and is not irrelevant.
Option E: Option E is incorrect: an H2 receptor antagonist is not a substitute for the antibiotics required to eradicate the organism.
4. [CASE 1 — QUESTION 4]
Continuing with the same patient. After eradication and with correctly timed pre-breakfast pantoprazole, his daytime symptoms resolve, but he still wakes at night with acid symptoms. What is the most appropriate addition, and why?
A) Switch to an as-needed antacid at night
B) Move the pantoprazole to bedtime
C) Add a bedtime H2 receptor antagonist, because nocturnal acid secretion is largely histamine-driven and relatively meal-independent, the pathway an H2 receptor antagonist most effectively targets, making it a logical supplement for nocturnal acid breakthrough
D) Add a second daytime pantoprazole dose
E) Discontinue acid suppression and observe
ANSWER: C
Rationale:
Nighttime acid secretion is predominantly histamine-driven and relatively independent of meals — exactly the pathway an H2 receptor antagonist blocks well. Because proton pump inhibitors act mainly on meal-recruited active pumps, nocturnal acid breakthrough can persist despite good daytime control; a bedtime H2 receptor antagonist targets the histamine-driven nighttime secretion.
Option A: Option A is incorrect: an antacid gives only brief relief and does not address sustained nocturnal secretion.
Option B: Option B is incorrect: moving the proton pump inhibitor to bedtime would sacrifice daytime control of the meal-driven surge.
Option D: Option D is incorrect: a second daytime proton pump inhibitor dose does not specifically address histamine-driven nocturnal secretion.
Option E: Option E is incorrect: stopping suppression would worsen his reflux.
5. [CASE 2 — QUESTION 1]
A 50-year-old woman in a large U.S. city presents with epigastric pain, and endoscopy reveals a duodenal ulcer with biopsy-confirmed Helicobacter pylori. She received clarithromycin-based therapy for a sinus infection last year, and local clarithromycin resistance exceeds 15 percent. Which first-line eradication regimen is most appropriate?
A) Clarithromycin triple therapy for 14 days
B) A proton pump inhibitor alone for 4 weeks
C) Clarithromycin triple therapy at a higher clarithromycin dose
D) Bismuth quadruple therapy — a proton pump inhibitor plus bismuth plus metronidazole plus tetracycline — which does not depend on clarithromycin and remains effective despite resistance or prior macrolide exposure
E) Amoxicillin monotherapy with an H2 receptor antagonist
ANSWER: D
Rationale:
Prior macrolide exposure and local clarithromycin resistance above 15 percent both predict failure of clarithromycin triple therapy. Bismuth quadruple therapy contains no clarithromycin and achieves high eradication rates regardless of clarithromycin resistance, making it the preferred first-line choice here.
Option A: Option A is incorrect: a clarithromycin-containing regimen is likely to fail in this setting.
Option B: Option B is incorrect: a proton pump inhibitor alone does not eradicate the organism.
Option C: Option C is incorrect: higher clarithromycin dosing does not overcome 23S rRNA target-site resistance.
Option E: Option E is incorrect: single-antibiotic therapy with an H2 receptor antagonist is inadequate and promotes resistance.
6. [CASE 2 — QUESTION 2]
Continuing with the same patient. She asks why the antibiotic she took last year might not work now. What is the molecular basis of clarithromycin resistance in Helicobacter pylori?
A) Point mutations in the 23S rRNA (ribosomal RNA) gene alter the ribosomal binding site so the macrolide can no longer bind its target
B) The bacterium secretes an enzyme that hydrolyzes the macrolide ring
C) Gastric acid destroys clarithromycin before it can act
D) Loss of a porin channel blocks all antibiotic entry
E) The bacterium forms a biofilm impervious to all drugs
ANSWER: A
Rationale:
Clarithromycin inhibits bacterial protein synthesis by binding ribosomal RNA. Resistance in Helicobacter pylori is principally target-site resistance: point mutations in the 23S rRNA gene change the macrolide binding site so the drug can no longer bind, which is why simply increasing the dose does not help.
Option B: Option B is incorrect: enzymatic hydrolysis of the macrolide is not the described mechanism in this organism.
Option C: Option C is incorrect: acid degradation is not the basis of clarithromycin resistance.
Option D: Option D is incorrect: generalized porin loss blocking all antibiotics is not the specific mechanism.
Option E: Option E is incorrect: biofilm formation is not the described resistance mechanism for clarithromycin here.
7. [CASE 2 — QUESTION 3]
Continuing with the same patient. She completes bismuth quadruple therapy, and you plan a urea breath test to confirm eradication. The test relies on active bacterial urease splitting labeled urea into detectable labeled carbon dioxide. How should she be prepared to avoid a false-negative result?
A) No preparation is needed; the test is unaffected by recent drugs
B) Restart the proton pump inhibitor the day before testing
C) Test immediately at the end of therapy for the most reliable result
D) Use serology instead, as it confirms cure most reliably
E) Withhold the proton pump inhibitor for about 2 weeks and antibiotics or bismuth for about 4 weeks before testing, because these agents suppress bacterial activity and can cause a false-negative even when organisms remain
ANSWER: E
Rationale:
The urea breath test depends on active bacterial metabolism. Proton pump inhibitors, antibiotics, and bismuth all suppress Helicobacter pylori activity and can drive a false-negative, so the proton pump inhibitor should be held for about 2 weeks and antibiotics or bismuth for about 4 weeks before testing.
Option A: Option A is incorrect: preparation is essential precisely because these drugs reduce detectable bacterial activity.
Option B: Option B is incorrect: restarting the proton pump inhibitor would suppress the organism and increase false-negative risk.
Option C: Option C is incorrect: testing immediately after therapy, before washout, risks a false-negative.
Option D: Option D is incorrect: serology cannot confirm eradication because antibodies persist after cure.
8. [CASE 2 — QUESTION 4]
Continuing with the same patient. She asks whether she could take a shorter 7-day course next time to reduce cost and make the pills easier to finish. Based on the evidence on treatment duration, what is the best response?
A) A 7-day course is equally effective and should be preferred for adherence
B) Extending eradication therapy from 7 to 14 days increases eradication rates by several percentage points, a meaningful gain when background resistance already lowers efficacy, so a 14-day course is recommended and shortening it risks failure and further resistance
C) Duration has no effect on eradication, so either is fine
D) A 3-day course is now standard
E) Only the proton pump inhibitor dose, not the duration, affects success
ANSWER: B
Rationale:
Evidence consistently shows that extending eradication therapy from 7 to 14 days improves eradication rates by several percentage points, a clinically meaningful gain especially when antibiotic resistance is already reducing efficacy. Current guidance favors 14-day duration, so shortening the course to cut cost or improve adherence is not justified and risks treatment failure with selection for further resistance.
Option A: Option A is incorrect: a 7-day course is less effective, not equally effective.
Option C: Option C is incorrect: duration does affect eradication.
Option D: Option D is incorrect: a 3-day course is not a standard eradication regimen.
Option E: Option E is incorrect: while adequate suppression matters, duration independently affects success and cannot be disregarded.
9. [CASE 3 — QUESTION 1]
A 28-year-old woman with rheumatoid arthritis requires chronic NSAID (non-steroidal anti-inflammatory drug) therapy. She is sexually active without reliable contraception, and pregnancy has not been excluded. She needs gastroprotection. Which agent is most appropriate?
A) Misoprostol, the best mechanistic match for NSAID injury
B) Low-dose misoprostol, considered safe early in pregnancy
C) A proton pump inhibitor, because misoprostol is absolutely contraindicated when pregnancy cannot be excluded and reliable contraception is not in place
D) No gastroprotection, given her age
E) On-demand antacids instead of a preventive agent
ANSWER: C
Rationale:
Misoprostol is a prostaglandin E1 analog that stimulates uterine contractions and is absolutely contraindicated in pregnancy (Pregnancy Category X), even at the gastroprotective dose. In a woman of childbearing potential without excluded pregnancy or reliable contraception, a proton pump inhibitor is the preferred gastroprotective agent.
Option A: Option A is incorrect: despite its mechanistic fit, misoprostol cannot be used here because of the pregnancy risk.
Option B: Option B is incorrect: there is no safe misoprostol dose in pregnancy; the contraindication is absolute.
Option D: Option D is incorrect: chronic NSAID therapy warrants gastroprotection regardless of age.
Option E: Option E is incorrect: on-demand antacids do not provide reliable prophylaxis for a chronic NSAID user.
10. [CASE 3 — QUESTION 2]
Continuing with the same patient. She asks how misoprostol would even work for stomach protection, since it is "not an acid pill." What is the correct explanation of its mechanism and of why NSAIDs damage the mucosa?
A) Misoprostol neutralizes stomach acid like an antacid
B) Misoprostol blocks the histamine H2 receptor
C) NSAIDs injure the mucosa only by direct contact, and misoprostol forms a physical coating
D) Misoprostol irreversibly inactivates the proton pump
E) NSAIDs inhibit cyclo-oxygenase and suppress the protective prostaglandins that maintain mucus, bicarbonate, and mucosal blood flow; misoprostol, a prostaglandin E1 analog, replaces that lost prostaglandin activity and restores mucosal defense
ANSWER: E
Rationale:
Gastric mucosal defense depends on prostaglandins that sustain mucus and bicarbonate secretion and mucosal blood flow. NSAIDs inhibit cyclo-oxygenase, suppressing these protective prostaglandins; the resulting injury is predominantly systemic rather than topical. Misoprostol is a prostaglandin E1 analog that restores prostaglandin-mediated protection, which is why it reduces NSAID ulcer risk.
Option A: Option A is incorrect: misoprostol does not neutralize acid; that is the antacid mechanism.
Option B: Option B is incorrect: it does not act at the histamine H2 receptor.
Option C: Option C is incorrect: NSAID injury is mainly systemic prostaglandin loss, and misoprostol works by supplying prostaglandin activity, not by coating.
Option D: Option D is incorrect: it does not inactivate the pump.
11. [CASE 3 — QUESTION 3]
Continuing with the same patient. She says a friend told her that an enteric-coated NSAID (non-steroidal anti-inflammatory drug) would protect her stomach so she would not need anything else. How should you respond, based on the mechanism of NSAID injury?
A) The friend is correct; enteric coating prevents NSAID ulcers
B) Enteric coating does not prevent NSAID ulcers, because the injury is predominantly a systemic consequence of cyclo-oxygenase inhibition and loss of protective prostaglandins, not topical contact of the tablet; the coating only changes where the tablet dissolves
C) Enteric coating works only if combined with calcium carbonate
D) Enteric coating eliminates the need for any acid suppression in all patients
E) The injury is purely topical, so enteric coating fully solves it
ANSWER: B
Rationale:
Because NSAID gastric toxicity is mainly a systemic effect of cyclo-oxygenase inhibition and the resulting loss of mucosal-protective prostaglandins, changing where the tablet dissolves does not prevent ulcers. This is precisely why enteric coating is not protective and why a pharmacologic gastroprotective strategy is still required.
Option A: Option A is incorrect: enteric coating does not prevent NSAID ulcers.
Option C: Option C is incorrect: pairing with calcium carbonate does not make enteric coating protective.
Option D: Option D is incorrect: enteric coating does not remove the need for gastroprotection.
Option E: Option E is incorrect: the injury is largely systemic, not purely topical, so coating does not solve it.
12. [CASE 3 — QUESTION 4]
Continuing with the same patient. Suppose that, after counseling, pregnancy is reliably excluded and she is using dependable contraception, but she genuinely cannot tolerate any proton pump inhibitor. Misoprostol is now considered. What is the most important counseling point about its tolerability, and what protection does it provide?
A) Misoprostol can reduce NSAID-induced ulcers but commonly causes dose-dependent diarrhea and abdominal cramping, which is the main reason patients stop it; she should be counseled about this and about strict avoidance of pregnancy while taking it
B) Misoprostol is free of gastrointestinal side effects
C) Misoprostol must be given intravenously for gastroprotection
D) Misoprostol provides no protection against NSAID ulcers
E) Misoprostol's only limitation is constipation
ANSWER: A
Rationale:
Misoprostol does reduce NSAID-induced gastric and duodenal ulcers, but its clinical use is limited chiefly by dose-dependent diarrhea and abdominal cramping, the principal reason patients discontinue it; this is essential counseling, alongside strict avoidance of pregnancy given its Category X status.
Option B: Option B is incorrect: it frequently causes gastrointestinal side effects.
Option C: Option C is incorrect: it is given orally for gastroprotection, not intravenously.
Option D: Option D is incorrect: it does provide meaningful protection against NSAID ulcers.
Option E: Option E is incorrect: its dose-limiting effect is diarrhea, not constipation.
13. [CASE 4 — QUESTION 1]
A 73-year-old woman has taken a proton pump inhibitor daily for several years for reflux and also takes digoxin for atrial fibrillation. She presents with muscle cramps and fatigue, and serum magnesium is low. After a course of oral magnesium, the level remains low. What is the most appropriate management, and why is the deficiency dangerous in her case?
A) Increase the oral magnesium dose and continue the proton pump inhibitor
B) Attribute the low magnesium to diet and make no change
C) Stop the digoxin, which is causing the hypomagnesemia
D) Add a second proton pump inhibitor to deepen suppression
E) Stop the proton pump inhibitor, because long-term acid suppression impairs intestinal magnesium absorption through the pH-dependent TRPM6 channel so oral magnesium cannot correct the deficit; this is especially dangerous here because hypomagnesemia potentiates digoxin toxicity and arrhythmias
ANSWER: E
Rationale:
Intestinal magnesium absorption via the TRPM6 channel depends on luminal acidity; long-term proton pump inhibitor use impairs it, producing hypomagnesemia. Because the defect is in absorption itself, oral magnesium is poorly absorbed and fails to correct the level, so the proton pump inhibitor must be stopped. The hazard is amplified by concurrent digoxin, where low magnesium potentiates toxicity and arrhythmias.
Option A: Option A is incorrect: more oral magnesium will not work while the absorptive defect persists.
Option B: Option B is incorrect: the temporal link and failure of oral repletion point to the drug, not diet.
Option C: Option C is incorrect: digoxin does not cause hypomagnesemia; the low magnesium worsens digoxin toxicity.
Option D: Option D is incorrect: additional acid suppression worsens the absorptive defect.
14. [CASE 4 — QUESTION 2]
Continuing with the same patient. Given her age and long-term proton pump inhibitor use, you discuss bone health and the observed association with fractures. If she needs calcium supplementation, which form is preferred and why?
A) Calcium carbonate, because it requires acid for absorption
B) Calcium citrate, because it does not require gastric acid for dissolution and is therefore better absorbed during acid suppression, unlike calcium carbonate
C) Either form equally, since acid suppression does not affect calcium absorption
D) No calcium is absorbable during proton pump inhibitor therapy
E) Calcium carbonate at a doubled dose
ANSWER: B
Rationale:
Long-term proton pump inhibitor use has been associated with fractures, attributed in part to impaired calcium absorption. Calcium carbonate depends on gastric acid for dissolution, so its absorption falls during acid suppression, whereas calcium citrate does not require acid and is better absorbed; calcium citrate is therefore preferred in proton pump inhibitor users.
Option A: Option A is incorrect: requiring acid makes calcium carbonate a poorer choice during suppression, not a better one.
Option C: Option C is incorrect: acid suppression does affect calcium carbonate absorption.
Option D: Option D is incorrect: calcium citrate remains absorbable during therapy.
Option E: Option E is incorrect: doubling an acid-dependent form does not reliably overcome the absorption problem; switching to citrate does.
15. [CASE 4 — QUESTION 3]
Continuing with the same patient. She is later hospitalized and develops diarrhea; the team is concerned about Clostridioides difficile (C. difficile) infection. How does long-term proton pump inhibitor use relate to this risk, mechanistically?
A) Proton pump inhibitors directly kill colonic bacteria, increasing C. difficile by clearing competitors
B) Proton pump inhibitors have no plausible relationship to C. difficile infection
C) Proton pump inhibitors increase C. difficile risk by raising stomach acid
D) Proton pump inhibitors raise gastric pH, and because gastric acid normally helps destroy ingested organisms, acid suppression allows greater survival of C. difficile and colonic colonization, an association supported by multiple epidemiological studies
E) Proton pump inhibitors cause C. difficile only when combined with calcium citrate
ANSWER: D
Rationale:
Gastric acid is part of the host defense that destroys ingested organisms. By raising gastric pH, proton pump inhibitors reduce this barrier, allowing greater survival of C. difficile and subsequent colonic colonization; multiple epidemiological studies support an increased risk, which argues for prescribing proton pump inhibitors only when clearly indicated, especially in hospitalized patients.
Option A: Option A is incorrect: the mechanism is reduced gastric acid killing of ingested organisms, not direct killing of colonic flora by the drug.
Option B: Option B is incorrect: a relationship is supported by the literature.
Option C: Option C is incorrect: proton pump inhibitors lower, not raise, gastric acidity.
Option E: Option E is incorrect: the risk is not contingent on calcium citrate co-use.
16. [CASE 4 — QUESTION 4]
Continuing with the same patient. After her acute issues resolve, you and she decide to discontinue the long-term proton pump inhibitor. What should you anticipate on withdrawal, and how should it be stopped?
A) Anticipate transient rebound acid hypersecretion from hypergastrinemia-driven ECL (enterochromaffin-like) cell hyperplasia, lasting 1 to 2 weeks; therefore taper gradually or step down to an H2 receptor antagonist rather than stopping abruptly
B) Anticipate nothing, because chronic suppression lowers gastrin permanently; stop abruptly
C) Double the dose for a week and then stop, which prevents rebound
D) Stop abruptly, since tapering prolongs symptoms
E) Add an antacid only after severe symptoms appear
ANSWER: A
Rationale:
Chronic acid suppression raises gastrin and drives ECL cell hyperplasia; abrupt withdrawal unmasks a transient rebound acid hypersecretion above baseline lasting one to two weeks. Because this is predictable, the rational approach is a gradual taper or step-down to an H2 receptor antagonist.
Option B: Option B is incorrect: chronic suppression raises gastrin rather than lowering it, and rebound does occur.
Option C: Option C is incorrect: increasing the dose before stopping deepens suppression and worsens compensatory hypergastrinemia.
Option D: Option D is incorrect: abrupt discontinuation provokes the rebound a taper is meant to soften.
Option E: Option E is incorrect: a structured taper is preferred over reactive antacid use after symptoms become severe.
17. [CASE 5 — QUESTION 1]
A 58-year-old man is mechanically ventilated in the ICU with normal renal function. The team wants stress ulcer prophylaxis but is specifically concerned about complications tied to raising intragastric pH, such as gastric bacterial overgrowth. Which agent's mechanism best fits this specific concern?
A) Sucralfate, because it protects the mucosa by forming an adherent barrier without raising intragastric pH, and has been associated in some trials with less ventilator-associated pneumonia than acid-suppressing agents
B) High-dose intravenous omeprazole, because it maximally raises gastric pH
C) Cimetidine, because broad enzyme inhibition is protective
D) Calcium carbonate antacid around the clock
E) An H2 receptor antagonist infusion titrated to a high gastric pH
ANSWER: A
Rationale:
The concern is specifically about consequences of raising gastric pH. Sucralfate provides mucosal protection through an adherent physical barrier and local defense stimulation without meaningfully raising intragastric pH, so gastric acidity is preserved and bacterial overgrowth is less favored; some trials associate it with less ventilator-associated pneumonia than pH-raising agents. With normal renal function, aluminum accumulation is not a concern.
Option B: Option B is incorrect: a high-dose intravenous proton pump inhibitor maximally raises pH, the opposite of what is wanted.
Option C: Option C is incorrect: cimetidine raises pH and adds broad drug interactions.
Option D: Option D is incorrect: a calcium carbonate antacid raises pH and is impractical for continuous prophylaxis.
Option E: Option E is incorrect: titrating an H2 receptor antagonist to high pH directly conflicts with the stated concern.
18. [CASE 5 — QUESTION 2]
Continuing with the same patient. Several days later he develops acute kidney injury that progresses, and his renal function does not recover well. How does this change the safety considerations for continued sucralfate use?
A) Renal function has no bearing on sucralfate safety
B) Sucralfate becomes safer in renal failure because it is more completely excreted
C) Sucralfate contains aluminum, and although systemic absorption is minimal with normal kidneys, impaired renal clearance allows aluminum to accumulate to clinically relevant levels, so sucralfate should be avoided or used with great caution in significant renal impairment
D) The aluminum in sucralfate is harmless regardless of renal function
E) Sucralfate should be switched to an aluminum-containing antacid instead
ANSWER: C
Rationale:
Sucralfate carries an aluminum load. With normal kidneys the small amount absorbed is cleared, but with significant renal impairment, reduced clearance allows aluminum to accumulate to clinically relevant concentrations, so sucralfate should be avoided or used with great caution as his renal function declines.
Option A: Option A is incorrect: renal function is exactly what governs aluminum accumulation risk.
Option B: Option B is incorrect: renal failure impairs aluminum clearance, making sucralfate less safe, not more.
Option D: Option D is incorrect: aluminum is not harmless when renal clearance is impaired.
Option E: Option E is incorrect: switching to an aluminum-containing antacid would not avoid the aluminum problem.
19. [CASE 5 — QUESTION 3]
Continuing with the same patient. While on sucralfate, he is also receiving enteral phenytoin and levothyroxine, and an oral fluoroquinolone is ordered. What administration principle protects the efficacy of these drugs?
A) No precautions are needed; sucralfate does not affect other drugs
B) All other drugs should be stopped while sucralfate is used
C) Sucralfate should be given intravenously to avoid interactions
D) Doubling each co-administered drug compensates for any binding
E) Sucralfate binds drugs such as fluoroquinolones, phenytoin, warfarin, digoxin, and thyroid hormone, reducing their absorption, so these agents should be separated from sucralfate by at least 2 hours
ANSWER: E
Rationale:
Sucralfate's adherent polymer binds a number of co-administered drugs — including fluoroquinolones, phenytoin, warfarin, digoxin, and thyroid hormone — reducing their absorption. The standard solution is temporal separation of at least 2 hours, which preserves absorption of the affected drugs while allowing sucralfate's local action.
Option A: Option A is incorrect: sucralfate has clinically relevant binding interactions.
Option B: Option B is incorrect: stopping needed drugs is unnecessary when doses are separated.
Option C: Option C is incorrect: sucralfate is given orally and acts locally; it is not given intravenously.
Option D: Option D is incorrect: dose doubling does not reliably overcome variable binding; separation is the correct approach.
20. [CASE 5 — QUESTION 4]
Continuing with the same patient. The team debates whether an intravenous proton pump inhibitor or an intravenous H2 receptor antagonist would have been better for stress ulcer prophylaxis in a ventilated patient. Which statement best reflects the current understanding of this trade-off?
A) Proton pump inhibitors are unequivocally superior in every respect, so H2 receptor antagonists should never be used in the ICU
B) H2 receptor antagonists provide no stress ulcer prophylaxis benefit at all
C) Antacids are the established first-line agent for stress ulcer prophylaxis in ventilated patients
D) Both intravenous proton pump inhibitors and intravenous H2 receptor antagonists are used for stress ulcer prophylaxis; some clinicians prefer agents that raise gastric pH less because of concerns about pH-related complications such as C. difficile (Clostridioides difficile) and ventilator-associated pneumonia, though the comparative evidence remains debated
E) The choice is purely arbitrary and no clinical considerations apply
ANSWER: D
Rationale:
Both intravenous proton pump inhibitors and intravenous H2 receptor antagonists are used for stress ulcer prophylaxis in critically ill ventilated patients. Because raising gastric pH may favor complications such as C. difficile infection and ventilator-associated pneumonia, some clinicians weigh that against the depth of acid suppression, and the comparative evidence between classes remains debated rather than settled.
Option A: Option A is incorrect: proton pump inhibitors are not unequivocally superior in all respects, and H2 receptor antagonists retain a role.
Option B: Option B is incorrect: H2 receptor antagonists do provide prophylaxis.
Option C: Option C is incorrect: antacids are not the established first-line stress ulcer prophylaxis agent here.
Option E: Option E is incorrect: real clinical considerations — including pH-related infection risk — inform the choice.
21. [CASE 6 — QUESTION 1]
A 68-year-old man has been taking cimetidine for several months for reflux. He reports new breast tenderness and enlargement and reduced libido. Which explanation and management are most appropriate for these new symptoms?
A) These symptoms are unrelated to cimetidine and need no medication change
B) Cimetidine blocks androgen receptors at higher doses, producing gynecomastia and sexual dysfunction in men; switching to famotidine, which lacks anti-androgenic activity while giving equivalent acid suppression, is appropriate
C) Cimetidine causes gynecomastia by irreversibly inhibiting the proton pump
D) The symptoms indicate a pituitary tumor and are not drug-related
E) Increasing the cimetidine dose will relieve the symptoms
ANSWER: B
Rationale:
Cimetidine blocks androgen receptors at higher doses, producing gynecomastia and sexual dysfunction in men. Because famotidine provides equivalent acid suppression without anti-androgenic effects, switching to famotidine is the appropriate management.
Option A: Option A is incorrect: these are recognized cimetidine effects, not unrelated symptoms.
Option C: Option C is incorrect: the mechanism is androgen-receptor blockade, not proton pump inhibition (cimetidine does not inhibit the pump).
Option D: Option D is incorrect: the combination points to cimetidine rather than a pituitary tumor.
Option E: Option E is incorrect: increasing the dose would intensify the anti-androgenic effect.
22. [CASE 6 — QUESTION 2]
Continuing with the same patient. Before switching agents, his laboratory work shows a modestly increased serum creatinine, but other measures suggest his actual glomerular filtration is stable and he has no signs of true kidney injury. What is the most likely explanation?
A) Cimetidine inhibits the renal tubular secretion of creatinine, raising serum creatinine even though the actual GFR (glomerular filtration rate) is unchanged
B) Cimetidine has caused acute tubular necrosis
C) Cimetidine increases creatinine production by muscle
E) The laboratory value is a pure assay artifact with no physiologic basis
ANSWER: A
Rationale:
Creatinine is both filtered and secreted by the proximal tubule. Cimetidine inhibits that tubular secretion, so serum creatinine rises even though glomerular filtration itself is unchanged. Recognizing this prevents misinterpreting the rise as true renal injury.
Option B: Option B is incorrect: this is a transport effect, not acute tubular necrosis.
Option C: Option C is incorrect: cimetidine does not increase muscle creatinine production.
Option D: Option D is incorrect: the GFR is stable, so this is not progressive renal failure.
Option E: Option E is incorrect: the rise reflects a real change in creatinine handling in the body, not an in-vitro artifact.
23. [CASE 6 — QUESTION 3]
Continuing with the same patient. He is also stabilized on warfarin and theophylline, and over the weeks on cimetidine he develops signs of toxicity from both. What best explains this, and what is the corrective step?
A) Cimetidine induced the metabolism of both drugs, lowering their levels
B) Cimetidine affects only renally cleared drugs, so warfarin and theophylline are unaffected
C) Cimetidine broadly inhibits several CYP isoforms (including CYP2C9 and CYP1A2), reducing clearance of narrow-therapeutic-index substrates such as warfarin and theophylline and raising their levels toward toxicity; switching to famotidine, which has negligible CYP inhibition, removes the interaction
D) The toxicity reflects cimetidine blocking the histamine H2 receptor on hepatocytes
E) The fix is to raise the warfarin and theophylline doses to match cimetidine
ANSWER: C
Rationale:
Cimetidine is a broad inhibitor of multiple CYP isoforms, including CYP2C9 (warfarin) and CYP1A2 (theophylline). Inhibiting their clearance raises the plasma levels of these narrow-therapeutic-index drugs toward toxicity. Switching to famotidine, which has negligible CYP inhibition, removes the interaction while maintaining acid suppression.
Option A: Option A is incorrect: cimetidine inhibits rather than induces these enzymes, so levels rise.
Option B: Option B is incorrect: cimetidine's CYP inhibition affects hepatically metabolized drugs like warfarin and theophylline.
Option D: Option D is incorrect: the mechanism is CYP inhibition, not H2 receptor blockade on hepatocytes.
Option E: Option E is incorrect: raising substrate doses worsens toxicity; removing the inhibitor is correct.
24. [CASE 6 — QUESTION 4]
Continuing with the same patient. You switch him to famotidine. Given that famotidine is eliminated largely unchanged by the kidney, what additional consideration applies as you dose it?
A) No dose consideration is needed, because famotidine is fully metabolized by the liver
B) Famotidine requires CYP2C19 genotyping before dosing
C) Famotidine must be avoided entirely in any patient over 65
D) Famotidine should be dosed higher in renal impairment because it is cleared faster
E) Because famotidine is predominantly excreted unchanged by the kidney, the dose should be reduced in patients with reduced renal function to avoid accumulation
ANSWER: E
Rationale:
Famotidine is eliminated mainly unchanged by renal excretion, so in patients with reduced glomerular filtration the dose should be reduced to avoid accumulation. This is particularly relevant in this older patient whose renal function should be monitored.
Option A: Option A is incorrect: famotidine is not primarily hepatically metabolized; its clearance is renal.
Option B: Option B is incorrect: famotidine does not require CYP2C19 genotyping (that consideration applies to proton pump inhibitor metabolism).
Option C: Option C is incorrect: famotidine is not contraindicated by age alone; it is preferred over cimetidine here.
Option D: Option D is incorrect: reduced renal function slows famotidine clearance, calling for a lower, not higher, dose.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.